Every investor in Regencell Bioscience Holdings Limited (NASDAQ:RGC) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to have institutions as shareholders. I quite like to see at least a little bit of insider ownership. As Charlie Munger said 'Show me the incentive and I will show you the outcome.
Regencell Bioscience Holdings is not a large company by global standards. It has a market capitalization of US$531m, which means it wouldn't have the attention of many institutional investors. Our analysis of the ownership of the company, below, shows that institutional investors have not yet purchased shares. We can zoom in on the different ownership groups, to learn more about Regencell Bioscience Holdings.
Check out our latest analysis for Regencell Bioscience Holdings
![ownership-breakdown](https://usnewsfile.futunn.com/pic/0-12397733-0-233ac5d8669af6cfce59d372523064ed.png/big)
NasdaqCM:RGC Ownership Breakdown July 12th 2022
What Does The Lack Of Institutional Ownership Tell Us About Regencell Bioscience Holdings?
Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them.
There could be various reasons why no institutions own shares in a company. Typically, small, newly listed companies don't attract much attention from fund managers, because it would not be possible for large fund managers to build a meaningful position in the company. It is also possible that fund managers don't own the stock because they aren't convinced it will perform well. Institutional investors may not find the historic growth of the business impressive, or there might be other factors at play. You can see the past revenue performance of Regencell Bioscience Holdings, for yourself, below.
![earnings-and-revenue-growth](https://usnewsfile.futunn.com/pic/0-12397733-1-f1c1c5641e3d5d2b66085e3e5e225fe5.png/big)
NasdaqCM:RGC Earnings and Revenue Growth July 12th 2022
Hedge funds don't have many shares in Regencell Bioscience Holdings. With a 81% stake, CEO Yat-Gai Au is the largest shareholder. With such a huge stake, we infer that they have significant control of the future of the company. It's usually considered a good sign when insiders own a significant number of shares in the company, and in this case, we're glad to see a company insider with such skin in the game. Digital Mobile Venture Ltd. is the second largest shareholder owning 7.6% of common stock, and Qube Research And Technologies Ltd holds about 0.1% of the company stock.
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
Insider Ownership Of Regencell Bioscience Holdings
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Company management run the business, but the CEO will answer to the board, even if he or she is a member of it.
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
Our information suggests that insiders own more than half of Regencell Bioscience Holdings Limited. This gives them effective control of the company. So they have a US$430m stake in this US$531m business. It is good to see this level of investment. You can check here to see if those insiders have been buying recently.
General Public Ownership
The general public-- including retail investors -- own 11% stake in the company, and hence can't easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
Private Equity Ownership
With an ownership of 7.6%, private equity firms are in a position to play a role in shaping corporate strategy with a focus on value creation. Some investors might be encouraged by this, since private equity are sometimes able to encourage strategies that help the market see the value in the company. Alternatively, those holders might be exiting the investment after taking it public.
Next Steps:
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Take risks for example - Regencell Bioscience Holdings has 1 warning sign we think you should be aware of.
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
脑再生科技控股有限公司(纳斯达克代码:RGC)的每一位投资者都应该知道最强大的股东群体。内部人士通常持有大量较年轻、规模较小的公司,而大公司往往有机构作为股东。我非常希望看到至少有一点内部人持股。正如查理·芒格所说,给我看激励措施,我就会告诉你结果。
以全球标准来看,脑再生科技控股并不是一家大公司。它的市值为5.31亿美元,这意味着它不会受到许多机构投资者的关注。我们对公司所有权的分析显示,机构投资者尚未购买股票。我们可以放大不同的所有权集团,了解更多关于脑再生科技控股的信息。
查看我们对脑再生科技控股的最新分析
![ownership-breakdown](https://usnewsfile.futunn.com/pic/0-12397733-0-233ac5d8669af6cfce59d372523064ed.png/big)
NasdaqCM:RGC所有权明细2022年7月12日
机构所有的缺失告诉了我们关于脑再生科技控股的什么信息?
交易不太活跃的小公司往往缺乏机构投资者,但大公司没有机构投资者的情况较少。
为什么没有机构持有一家公司的股票,可能有各种原因。通常情况下,新上市的小型公司不会引起基金经理太多关注,因为大型基金管理公司不可能在该公司建立有意义的头寸。基金经理也有可能不持有这只股票,因为他们不相信它会表现良好。机构投资者可能不会觉得这项业务的历史性增长令人印象深刻,或者可能有其他因素在起作用。你可以在下面看到脑再生科技控股过去的收入表现,为你自己。
![earnings-and-revenue-growth](https://usnewsfile.futunn.com/pic/0-12397733-1-f1c1c5641e3d5d2b66085e3e5e225fe5.png/big)
纳斯达克CM:RGC收益和收入增长2022年7月12日
对冲基金在脑再生科技控股的股份并不多。行政总裁区逸杰持有81%的股份,是最大股东。拥有如此庞大的股份,我们推断他们对公司的未来有很大的控制权。当内部人持有公司大量股份时,这通常被认为是一个好兆头,在这种情况下,我们很高兴看到公司内部人士有这样的皮肤。Digital Mobile Venture Ltd.是第二大股东,持有7.6%的普通股,Qube Research and Technologies Ltd持有约0.1%的公司股票。
虽然研究一家公司的机构所有权数据是有意义的,但研究分析师的情绪以了解风向也是有意义的。我们的信息显示,分析师没有对该股进行任何报道,因此它可能鲜为人知。
脑再生科技控股的内部人所有权
尽管对内部人的准确定义可能是主观的,但几乎每个人都认为董事会成员是内部人。公司管理层管理企业,但首席执行官将向董事会负责,即使他或她是董事会成员。
内部人持股是积极的,当它标志着领导层像公司的真正所有者一样思考时。然而,高内部人持股也可以给公司内部的一个小团体带来巨大的权力。在某些情况下,这可能是负面的。
我们的信息显示,内部人士拥有脑再生科技控股有限公司一半以上的股份。这让他们有效地控制了公司。因此,他们在这项价值5.31亿美元的业务中持有4.3亿美元的股份。很高兴看到这样的投资水平。你可以在这里查看这些内部人士最近是否一直在买入。
一般公有制
包括散户投资者在内的普通公众持有该公司11%的股份,因此不能轻易忽视。尽管这种规模的所有权可能不足以影响有利于他们的政策决定,但他们仍然可以对公司政策产生集体影响。
私募股权所有权
私募股权公司拥有7.6%的股权,能够在塑造专注于价值创造的公司战略方面发挥作用。一些投资者可能会因此而受到鼓舞,因为私人股本有时能够鼓励有助于市场看到公司价值的策略。或者,这些持有者可能会在投资上市后退出。
接下来的步骤:
虽然考虑拥有一家公司的不同集团是很值得的,但还有其他更重要的因素。以风险为例-脑再生科技控股拥有1个警告标志我们认为你应该意识到。
当然了,如果你把目光投向别处,你可能会发现这是一笔很棒的投资。所以让我们来看看这个免费有趣的公司名单。
注:本文中的数字是使用过去12个月的数据计算的,指的是截至财务报表日期的最后一个月的12个月期间。这可能与全年的年度报告数字不一致。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。